个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
首都医科大学附属北京地坛医院副院长，主任医师，教授，博士生导师；北京市卫生系统高层次人才，北京市医管中心“登峰”人才，第六批全国老中医药专家学术经验继承人（师承姚树坤教授）；北京中西医结合肝病学会主任委员、中华中医药学会肝胆病分会常委等。承担自然基金4项，以第一作者或通讯作者发表学术论文60余篇，其中SCI 37篇，获发明专利11项，省级以上奖励4项。主要从事中医药治疗原发性肝癌的免疫学临床与机制研究。
代表性科研项目：
1. 国家自然科学基金面上项目（编号：30873423），苦参碱对细胞增殖模型大鼠卵圆细胞向肝细胞的诱导分化及Notch信号通路的调节作用
2. 北京市自然科学基金资助项目（编号：7142081），WNT信号通路在慢性乙型肝炎肝纤维化进程中作用及凉血解毒方干预机制研究
3. 国家自然科学基金面上项目,（编号：81874435），养阴扶正解毒方逆转T细胞功能耗竭治疗乙肝相关原发性肝癌的机制研究
4. 北京市医院管理中心“登峰”计划专项（编号：DFL20191803），2019年度（第三期）“登峰”人才培养-中西医结合重症肝病
5. 首都卫生发展科研专项（编号：2020-2-2173），基于“CD45+红系前体细胞”探讨养阴扶正解毒法治疗乙肝肝癌相关贫血的疗效评价
重要学术论文：
1) Zhang S, He LL, Wang XH, et al. A novel scoringmodel for predicting mortality risk in patients with cirrhosis and hepatorenalsyndrome. Eur J Gastroenterol Hepatol. 2018;30(8):938-943.doi:10.1097/MEG.0000000000001127IF: 2.1 Q4 （IF:2.198）
2) Liu X, Li M, Wang X, et al. Effect of serumtriglyceride level on the prognosis of patients with hepatocellular carcinomain the absence of cirrhosis. Lipids Health Dis. 2018;17(1):248. Published 2018 Nov 6.doi:10.1186/s12944-018-0898-y（IF:2.663）
3) Li M, Zhao Y, Liu X, et al. Association andinteraction between model for end-stage liver disease score and minimallyinvasive treatment with regard to mortality of patients with hepatitis Bvirus-associated hepatocellular carcinoma and portal vein tumor thrombi. Oncol Lett. 2019;17(1):119-126. doi:10.3892/ol.2018.9590（IF:2.311）
4) Dang Z, Liu X, Wang X, et al. Comparativeeffectiveness and safety of traditional Chinese medicine supporting Qi andenriching blood for cancer related anemia in patients not receivingchemoradiotherapy: a meta-analysis and systematic review. Drug Des Devel Ther. 2018;13:221-230. Published 2018 Dec 28.doi:10.2147/DDDT.S181182（IF:3.216）
5) He LL, Liu XL, Zhang S, et al. Independent riskfactors for disease recurrence after surgery in patients with hepatitis Bvirus-related hepatocellular carcinoma ≤3 cm in diameter. Gastroenterol Rep (Oxf). 2019;7(4):250-257. doi:10.1093/gastro/goz009（IF:2.96）
6) Wang X, Liu X, Dang Z, et al. Nucleos(t)ideAnalogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis BPatients: A Systematic Review and Meta-Analysis. Gut Liver. 2020;14(2):232-247. doi:10.5009/gnl18546（IF:4.519）
7) Liu X, Li M, Wang X, et al. Effects of adjuvanttraditional Chinese medicine therapy on long-term survival in patients withhepatocellular carcinoma. Phytomedicine. 2019;62:152930. doi:10.1016/j.phymed.2019.152930（IF:4.268）
8) Yu L, Liu X, Wang X, et al. Impact of gender asa prognostic factor in HBV-related Hepatocellular Carcinoma: the survivalstrength of female patients in BCLC stage 0-B. J Cancer. 2019;10(18):4237-4244. Published 2019 Jul 10.doi:10.7150/jca.33430（IF:3.565）
9) Li M, Zhao Y, Liu X, Zhang S, Jiang Y, Yang Z.Early risk warning system for distant metastasis of hepatitis Bvirus-associated hepatocellular carcinoma with portal vein tumor thrombus. Oncol Lett. 2020;19(4):3249-3257. doi:10.3892/ol.2020.11423（IF:2.967）
10) Liu X, Li M, Wang X, et al. PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis andprogression of patients with hepatitis B virus-related hepatocellularcarcinoma. Cancer Immunol Immunother. 2019;68(12):2041-2054.doi:10.1007/s00262-019-02426-5（IF:5.442）
11) Liu X, Hou Y, Wang X, et al. Machinelearning-based development and validation of a scoring system forprogression-free survival in liver cancer. Hepatol Int. 2020;14(4):567-576.doi:10.1007/s12072-020-10046-w（IF:6.047）
12) Yan F, Feng M, Wang X, et al. Molecular targetsof Yangyin Fuzheng Jiedu Prescription in the treatment of hepatocellularcarcinoma based on network pharmacology analysis. Cancer Cell Int. 2020;20(1):540. Published 2020 Nov 9.doi:10.1186/s12935-020-01596-y（IF:5.722）
13) Yu L, Liu X, Jiang Y, Wang X, Wang X, Yang Z.Use of a Novel Thyroid-Stimulating Hormone Model for Predicting the Progressionof Hepatocellular Carcinoma. Onco Targets Ther. 2020;13:11421-11431. Published 2020 Nov 6.doi:10.2147/OTT.S275304（IF:4.147）
14) Hou Y, Zhang Q, Gao F, et al. Artificial neuralnetwork-based models used for predicting 28- and 90-day mortality of patientswith hepatitis B-associated acute-on-chronic liver failure. BMC Gastroenterol. 2020;20(1):75. Published 2020 Mar 13.doi:10.1186/s12876-020-01191-5IF: 2.4 Q4 （IF:3.067）
15) Liu X, Lu J, Zhang G, et al. A Machine LearningApproach Yields a Multiparameter Prognostic Marker in Liver Cancer. Cancer Immunol Res. 2021;9(3):337-347.doi:10.1158/2326-6066.CIR-20-0616（IF:11.151）
16) Zhou D, Liu X, Wang X, et al. A prognosticnomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negativehepatocellular carcinoma following non-surgical therapy. BMC Cancer. 2021;21(1):246. Published 2021 Mar 8.doi:10.1186/s12885-021-07916-3（IF:4.43）
17) Yu L, Liu X, Wang X, et al. TIGIT+ TIM-3+ NK cells are correlated with NK cellexhaustion and disease progression in patients with hepatitis B virus‑relatedhepatocellular carcinoma. Oncoimmunology. 2021;10(1):1942673. Published 2021 Jun 28.doi:10.1080/2162402X.2021.1942673（IF:8.11）
18) Jiang TT, Liu XL, Jiang YY, Wang XB, Yang ZY.Minimal Hepatic Encephalopathy and Biejia-Ruangan Are Associated with FirstHospital Readmission in Nonalcoholic Cirrhosis Patients. Evid Based Complement Alternat Med. 2021;2021:6652858. Published 2021 May 7.doi:10.1155/2021/6652858（IF:2.629）
19) Yan F, Wang X, Xie Y, et al. Yangyin FuzhengJiedu Prescription exerts anti-tumor immunity in hepatocellular carcinoma byalleviating exhausted T cells. Phytomedicine. 2021;91:153722. doi:10.1016/j.phymed.2021.153722(IF:5.340）
20) Wang X, Liu X, Wang P, et al. Antiviral TherapyReduces Mortality in Hepatocellular Carcinoma Patients with Low-Level HepatitisB Viremia. J Hepatocell Carcinoma. 2021;8:1253-1267. Published 2021 Oct 21.doi:10.2147/JHC.S330301(IF: 5.84）
21) Yu L, Liu X, Wang X, et al. Nomogram forprediction of long-term survival with hepatocellular carcinoma based on NK cellcounts. Ann Hepatol. 2022;27(2):100672.doi:10.1016/j.aohep.2022.100672IF: 3.8 Q2 (IF:2.4）
22) Yan H, Wang X, Liu X, et al. The survivalstrength of younger patients in BCLC stage 0-B of hepatocellular carcinoma:basing on competing risk model. BMC Cancer. 2022;22(1):185. Published 2022 Feb 18.doi:10.1186/s12885-022-09293-x（IF:4.43）
23) Yan H, Wang X, Zhou D, Wang P, Yang Z. DynamicNomogram for Predicting Macrovascular Invasion of Patients with UnresectableHepatocellular Carcinoma after Transarterial Chemoembolization. J Cancer. 2022;13(6):1914-1922. Published 2022 Mar 28.doi:10.7150/jca.69548（IF:4.207）
24) Liu X, Wang X, Yu L, et al. A Novel PrognosticScore Based on Artificial Intelligence in Hepatocellular Carcinoma: A Long-TermFollow-Up Analysis. Front Oncol. 2022;12:817853. Published 2022 May 31.doi:10.3389/fonc.2022.817853IF: 4.7 Q2 （IF:6.2）
25) Yu L, Liu X, Wang X, et al.Glycometabolism-related gene signature of hepatocellular carcinoma predictsprognosis and guides immunotherapy. Front Cell Dev Biol. 2022;10:940551. Published 2022 Jul 22.doi:10.3389/fcell.2022.940551（IF:6.0）
重要奖项：
1)解毒凉血健牌法提高慢加急性肝衰竭疗效的创新技术建立及推广应用2017年中华医学科技奖 二等奖201702
2)解毒凉血健牌法提高慢加急性肝衰竭疗效的创新技术建立及推广应用2016年北京市科学技术奖 三等奖201603
3)解毒凉血健牌法提高慢加急性肝衰竭疗效的创新技术建立及推广应用2018年华夏医学科技奖 二等奖201802
4)解毒凉血健牌法提高慢加急性肝衰竭疗效的创新技术建立及推广应用2016年北京医学科技奖 三等奖201603
文件上传中...
